WO2023141560A3 - Alkaline phosphatase for use in oncology - Google Patents

Alkaline phosphatase for use in oncology Download PDF

Info

Publication number
WO2023141560A3
WO2023141560A3 PCT/US2023/060978 US2023060978W WO2023141560A3 WO 2023141560 A3 WO2023141560 A3 WO 2023141560A3 US 2023060978 W US2023060978 W US 2023060978W WO 2023141560 A3 WO2023141560 A3 WO 2023141560A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncology
cancer therapy
alkaline phosphatase
iap
laps
Prior art date
Application number
PCT/US2023/060978
Other languages
French (fr)
Other versions
WO2023141560A2 (en
Inventor
Michael Kaleko
Original Assignee
Synthetic Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics, Inc. filed Critical Synthetic Biologics, Inc.
Publication of WO2023141560A2 publication Critical patent/WO2023141560A2/en
Publication of WO2023141560A3 publication Critical patent/WO2023141560A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates, inter alia, to combination therapies of specific commensal gastrointestinal bacteria with therapeutic intestinal alkaline phosphatases (lAPs) for preventing, treating, and/or reducing a cancer therapy-mediated side effect, or improving efficacy of a cancer therapy relative to the treatment before or in the absence of IAP.
PCT/US2023/060978 2022-01-20 2023-01-20 Alkaline phosphatase for use in oncology WO2023141560A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263301227P 2022-01-20 2022-01-20
US63/301,227 2022-01-20

Publications (2)

Publication Number Publication Date
WO2023141560A2 WO2023141560A2 (en) 2023-07-27
WO2023141560A3 true WO2023141560A3 (en) 2023-09-21

Family

ID=87349170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060978 WO2023141560A2 (en) 2022-01-20 2023-01-20 Alkaline phosphatase for use in oncology

Country Status (1)

Country Link
WO (1) WO2023141560A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036144A1 (en) * 2022-08-09 2024-02-15 Theriva Biologics, Inc. Treatment or prevention of gastrointestinal immunotherapy side effects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020163381A1 (en) * 2019-02-04 2020-08-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
US20200277379A1 (en) * 2019-03-01 2020-09-03 Rampart Health, L.L.C. Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer
WO2020247421A1 (en) * 2019-06-03 2020-12-10 Synthetic Biologics, Inc. Alkaline phosphatase formulations and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020163381A1 (en) * 2019-02-04 2020-08-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
US20200277379A1 (en) * 2019-03-01 2020-09-03 Rampart Health, L.L.C. Pharmaceutical composition combining immunologic and chemotherapeutic method for the treatment of cancer
WO2020247421A1 (en) * 2019-06-03 2020-12-10 Synthetic Biologics, Inc. Alkaline phosphatase formulations and uses thereof

Also Published As

Publication number Publication date
WO2023141560A2 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2020008777A (en) Microbiome related immunotherapies.
WO2023141560A3 (en) Alkaline phosphatase for use in oncology
MXPA05011656A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis.
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
EA201650134A1 (en) SPECIFIC COMBINED THERAPY OF MALIGNANT TUMORS BY CYTOSTATIC AND ITS MODIFIER
MX2023004156A (en) Combination therapy for treating cancer.
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
IL155781A0 (en) Effective antitumor treatments
MX2009011320A (en) Enzymatic anticancer therapy.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2023006793A (en) Combination therapies for treatment of her2 cancer.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2021008972A (en) Metal chelator combination therapy for the treatment of cancer.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
UA86586C2 (en) Combination for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
WO2021229507A3 (en) Methods, therapies and uses for treating cancer
MX2022011845A (en) Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor.
MX2022014223A (en) Combination therapy for ttr amyloidosis.
TW200724158A (en) Combination therapy in the treatment of cancer
AU2020327022A8 (en) Method of treating cancer
MX2021006778A (en) Novel approach for treatment of cancer using immunomodulation.
WO2023164455A3 (en) Compositions and methods to modulate the immune system
MX2021002884A (en) Combination therapy for the treatment of prostate cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743945

Country of ref document: EP

Kind code of ref document: A2